EUVIMEDEUVIMED entdecken
Multizentrische Studie

Progression of Loss of Vision From Centre‐Involving Macular Atrophy in Eyes Treated for nAMD

Kelvin Y C Teo iD, Theodorus Leonardus Ponsioen, Sioe Lan, Louise OToole, Carolina Arruabarrena Sanchez, Richard Barry, Helena Brosa Morros, Charmaine Chung, Alessandro Invernizzi iD, Gemmy Chui Ming Cheung, Daniel Barthelmes, Mark C Gillies

Clinical & Experimental Ophthalmology · 2025

DOI: 10.1111/ceo.14587 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical & Experimental Ophthalmology, 2025. Verfasst von Kelvin Y C Teo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Singapore Eye Research Institute, Singapore, Singapore. Hauptthemen laut MEDLINE: Visual Acuity, Wet Macular Degeneration, Macula Lutea, Blindness. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Australian and New Zealand Eye Foundation, National Health and Medical Research Council, Australia, Macula Disease Foundation, Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aimed to characterise visual acuity (VA) changes in eyes without baseline macular atrophy (MA) that subsequently developed MA during treatment for neovascular age‐related macular degeneration (nAMD).

Methods

A case–control analysis was performed using data from a multicentre real‐world AMD registry. We compared VA outcomes in 1998 treatment‐naïve eyes without MA at baseline and ≥ 5 years of follow‐up. Two matched groups (999 eyes each) were analysed: eyes that developed incident MA and those that never did.

Results

Comparisons were made between two matched groups of 999 eyes each with incident MA and those that never developed it with at least 5 years of follow‐up. Final VA was best in eyes that never developed MA, followed by eyes that developed extrafoveal and sub‐foveal MA (68.9 ± 16.7, 67.0 ± 16.9 and 52.1 ± 23.6 letters, p < 0.01). Eyes with incident MA had more inactive disease visits compared to those that never developed MA. Features associated with poor final VA included the presence of sub‐foveal MA (odds ratio [OR] [95% confidence interval (CI)] −16.63 [−18.7 to 14.56], p < 0.01) and a higher proportion of active visits (per 10%) (OR [95% CI] −0.73 [−1.12 to 0.34], p < 0.01). The mean time to lose five letters of vision from first grading of sub‐foveal MA was 17.3 ± 4.6 months.

Conclusion

It is important to achieve disease inactivity in nAMD despite its association with incident MA, as neovascular complications play a significant role in VA loss. The long duration between the incidence of MA and clinically significant loss of vision offers an opportunity for potential interventions against atrophy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Visual AcuityWet Macular DegenerationMacula LuteaBlindnessHumansFemaleMaleAgedDisease ProgressionCase-Control StudiesAngiogenesis InhibitorsFollow-Up StudiesTomography, Optical CoherenceAged, 80 and overRegistriesIntravitreal InjectionsVascular Endothelial Growth Factor ARanibizumabFluorescein AngiographyRetrospective StudiesMiddle AgedIncidenceAtrophy

Stichwörter der Autor:innen

age‐related macular degenerationanti‐VEGFatrophygeographic atrophymacular atrophy

Substanzen

Angiogenesis InhibitorsVascular Endothelial Growth Factor ARanibizumabVEGFA protein, human

Autor:innen und Institutionen

  • Singapore Eye Research Institute, Singapore, Singapore.
  • Advanced Eye Clinic and Surgery, Singapore, Singapore.
  • Save Sight Institute, The University of Sydney, Sydney, Australia.
  • Department of Ophthalmology, Isala Clinic, Zwolle, the Netherlands.
  • Department of Ophthalmology, Gelre Hospital, Apeldoorn, the Netherlands.
  • Mater Private Network Dublin, Dublin, Ireland.

ORCID-Profile: Kelvin Y C Teo, Alessandro Invernizzi

Förderung

  • Australian and New Zealand Eye Foundation
  • National Health and Medical Research Council, Australia
  • Macula Disease Foundation, Australia
  • Walter and Gertrud Siegenthaler Foundation
  • Swiss National Science Foundation
  • National Health and Medical Research Council
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Teo, K. Y. C., Ponsioen, T. L., Lan, S., OToole, L., Arruabarrena Sanchez, C., Barry, R., Morros, H. B., Chung, C., Invernizzi, A., Cheung, G. C. M., Barthelmes, D., & Gillies, M. C. (2025). Progression of Loss of Vision From Centre‐Involving Macular Atrophy in Eyes Treated for nAMD. Clinical & Experimental Ophthalmology. https://doi.org/10.1111/ceo.14587

Vancouver

Teo KYC, Ponsioen TL, Lan S, OToole L, Arruabarrena Sanchez C, Barry R, et al. Progression of Loss of Vision From Centre‐Involving Macular Atrophy in Eyes Treated for nAMD. Clinical & Experimental Ophthalmology. 2025. doi:10.1111/ceo.14587

BibTeX
@article{Teo2025,
  author = {Teo, Kelvin Y C and Ponsioen, Theodorus Leonardus and Lan, Sioe and OToole, Louise and Arruabarrena Sanchez, Carolina and Barry, Richard and Morros, Helena Brosa and Chung, Charmaine and Invernizzi, Alessandro and Cheung, Gemmy Chui Ming and Barthelmes, Daniel and Gillies, Mark C},
  title = {Progression of Loss of Vision From Centre‐Involving Macular Atrophy in Eyes Treated for nAMD},
  journal = {Clinical & Experimental Ophthalmology},
  year = {2025},
  doi = {10.1111/ceo.14587}
}
Kostenlos starten →